Sign in

    John Cox

    Managing Director and Senior Equity Research Analyst at Jefferies

    John Cox is a Managing Director and Senior Equity Research Analyst at Jefferies, specializing in the utilities and independent power producer sectors. He covers key companies such as NextEra Energy, Duke Energy, and NRG Energy, with a strong performance record that has included a TipRanks analyst ranking among the top 25% for accuracy and average returns exceeding 9% per year over a five-year period. Cox began his investment research career in the early 2000s, previously holding positions at Credit Suisse and Lehman Brothers before joining Jefferies in 2010. He is a FINRA-registered representative holding Series 7, 63, and 86/87 securities licenses, recognized for his in-depth research and influential sector insights.

    John Cox's questions to SUPERNUS PHARMACEUTICALS (SUPN) leadership

    John Cox's questions to SUPERNUS PHARMACEUTICALS (SUPN) leadership • Q2 2025

    Question

    John Cox, on behalf of Jefferies, asked about the drivers behind ZERZUVEY's Q2 sales acceleration, its future growth trajectory, peak sales potential, and the company's interest in pursuing other indications like MDD.

    Answer

    CEO Jack Khattar stated that while Supernus just closed the acquisition, Sage had reported strong organic momentum for ZERZUVEY, with 36% prescription growth in Q2. He deferred providing specific peak sales figures but pointed to the deal's milestone structure as an indicator of their expectations. Khattar noted that any decisions on future indications would be made jointly with their partner, Biogen.

    Ask Fintool Equity Research AI